ConductScience.org, home

Paper20099

Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata).

Vesely DL and 4 others. Biochem Biophys Res Commun, 1977. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata). Papers, record 20099. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20099

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata).
PubMed
Journal
Biochem Biophys Res Commun
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.78
iCite
Revised in PubMed
2019-06-12
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vesely DLD L
2Graves WRW R
3Lo TMT M
4Fletcher MAM A
5Levey GSG S

Source PubMed

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Enzyme InhibitorsMajor topic
Guanylate CyclaseMajor topic
Plant ExtractsMajor topic
Animals
Fruit
Liver
Male
Methylnitronitrosoguanidine
Molecular Weight
Plant Poisoning
Rats
Seeds
Streptozocin

Source PubMed

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
30,262,975Molecular docking analysis of phytoconstituent from Momordica charantia with Guanylate Cyclase catalytic domain.Bioinformation2018https://conductscience.org/library/papers/30262975PubMed
27,452,666Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.Semin Cancer Biol2016https://conductscience.org/library/papers/27452666PubMed
22,654,956Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells.Evid Based Complement Alternat Med2012https://conductscience.org/library/papers/22654956PubMed
44,704Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate.Infect Immun1979https://conductscience.org/library/papers/44704PubMed
40,226Testosterone and its precursors and metabolites enhance guanylate cyclase activity.Proc Natl Acad Sci U S A1979https://conductscience.org/library/papers/40226PubMed
24,847Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/24847PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20099

GET https://conductscience.org/api/papers/v1/20099/authors